'Acute myeloid leukemia: a comprehensive review and 2016 update' - Test2 - elhamkhani - TriplyDB

'Acute myeloid leukemia: a comprehensive review and 2016 update'

'Acute myeloid leukemia: a comprehensive review and 2016 update'

http://www.wikidata.org/entity/Q28072539

about

Chromosome t(7;11)(p15;p15) translocation in acute myeloid leukemia coexisting with multilineage dyspoiesis and mutations in NRAS and WT1: A case report and literature review Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia.Sequencing thousands of single-cell genomes with combinatorial indexing.Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.LRRC25 plays a key role in all-trans retinoic acid-induced granulocytic differentiation as a novel potential leukocyte differentiation antigen.Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.Rhabdomyolysis as a rare paraneoplastic presentation of acute myeloid leukemia.Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis.Zebrafish in Translational Cancer Research: Insight into Leukemia, Melanoma, Glioma and Endocrine Tumor Biology.Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment.Antibody darts on target for acute myelogenous leukemia.Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system.Silibinin: an old drug for hematological disorders.The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.Modeling Myeloid Malignancies Using Zebrafish.Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML.(Immuno)proteasomes as therapeutic target in acute leukemia.Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.Clinical Impact of Genomic Information in Pediatric Leukemia.Targeting oncoproteins for degradation by small molecules in myeloid leukemia.microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.Inhibition of USP10 induces degradation of oncogenic FLT3.Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.Cancer-related mRNA expression analysis using a novel flow cytometry-based assay.SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer.Vav1 is necessary for PU.1 mediated upmodulation of miR-29b in acute myeloid leukaemia-derived cells.MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Emerging function of N6-methyladenosine in cancer Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches

P2860

Q33684901-AD721A05-8C40-48F5-B1A8-BA0EAD39ADE0 Q33889046-B5BA6767-DE4C-4DC2-9262-AF7A0B905CAE Q36263746-D9E0D302-4183-4E0A-BBA5-B1236966F2B9 Q38701636-EFB207BD-36C4-4CF0-84AE-11F51F2CD75C Q38768045-5C2E2F20-23E6-4536-8617-A767ACF5BE8D Q39282540-9A7D8CFF-47E2-4C57-82D4-F0C46C271574 Q40066265-93729FC5-1E48-4F2D-926F-1411272F5F7A Q40962550-53BEE401-9B24-4B34-A8A9-97A8CF1B0EB8 Q41530049-5B3B3312-4D91-4BA4-B30A-1DC40A448822 Q41673513-DB1F8A74-FCCF-4FAD-9D4D-D82AADF49815 Q42229089-AEDC0642-BDCF-47E4-B06A-B54A6F6C4FA7 Q42318343-D653E8E1-2A19-46E3-BCD8-68CE39764F57 Q44807937-BCFD8175-EB98-4F0B-8F5D-F44AE77A3DC3 Q45747315-54821961-E908-490B-A6FC-C4A68F37E027 Q45865484-4489CDA0-8D85-415F-A15A-C9A04BBB6243 Q46300745-844A3B71-F966-4773-A7AE-2A18FCEECD21 Q46721176-5D36AF4D-1298-4A84-B63C-82D49246A8F5 Q47103190-ADF10AFF-44F9-4A9D-BBDA-0243D1C45384 Q47108992-77C0157E-71D8-4FDB-9559-F22481D70294 Q47110722-2B095B79-0CAE-4FF2-A15D-E3EBD452ACA3 Q47131929-1E7B3AC1-19D0-41D5-A342-FA1E0F7B3756 Q47136441-507DF136-303B-421E-8E6C-925BE9A4A465 Q47221791-4234F4E5-222A-4C1B-9DAC-1E4FDE43143D Q47337952-ABC482BD-AA6C-429A-8FEF-5367B656F1FC Q47375547-622F57A1-D5CA-4274-8C0B-06A56C82D813 Q47716589-AD6420C5-3069-4590-92B4-4E2571CD809F Q47808353-D9124D05-D230-4E7D-80C7-AD72C9D59502 Q47859984-A4C96CE6-7C5E-4B7C-B01F-462022D86CF1 Q47956417-65037FC2-218B-4134-8DF9-30E7AD814D4B Q48104779-0691DF75-A25A-442D-B108-6C57AF3B416D Q49656307-3B9A3477-C3AE-47B4-9239-378662BEB9A5 Q51734400-42541FBF-602C-4FB8-9AA8-B59A16994F3E Q51760643-4B899010-AB1B-40D3-945A-C76B75468A4F Q52716912-5FD126D6-E050-4514-9B28-D532DD0E0C5D Q57143658-023F2B16-5047-4296-A397-2D3D06291A62 Q57788856-9CAF5F39-62CA-4F93-85DD-A6BE8EB71CF6 Q58580432-BDB80269-9879-4EA3-B6A7-F8882DD70491 Q58692793-09A25499-992D-4F5E-ABEC-DA631FA4AC4F

P2860

'Acute myeloid leukemia: a comprehensive review and 2016 update'

http://www.wikidata.org/entity/Q28072539

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@ast

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@en

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@nl

type

label

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@ast

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@en

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@nl

prefLabel

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@ast

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@en

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@nl

P1433

Q28072539-97BF78B2-FA4F-49DD-91DA-753706A4490B

P1476

Q28072539-F90810EA-4C0D-415B-88DF-E9DD2F0212F9

P2093

Q28072539-9758F479-CC6E-4348-8058-9A0F46BDFDE5

P275

Q28072539-C104E91B-357D-4CFD-A50F-8F3B19B83A87

P2860

Q28072539-02E209D9-59D9-4FDD-AA50-5068D53AFCB1

Q28072539-05536F20-D4C1-4A52-8796-AA47E6E7A159

Q28072539-06443E18-1F98-438E-99DC-EE5994B3294B

Q28072539-07670C8B-160E-4920-AB52-56D3E092C0F6

Q28072539-0B70A9B4-9897-4781-AB66-7DDA761C00FF

Q28072539-0BFDE40F-3F35-4428-A6E0-4AAC87A9990D

Q28072539-0EA10E2C-6BC9-4CDD-B5C4-CE044E3C12D6

Q28072539-13C1D6D5-D0BE-4588-9FAC-EDA169DA1FA3

Q28072539-13CF13DE-662A-44BD-9D97-0AE2AFDA029B

Q28072539-13EEF1C6-3928-4B33-8EBB-39BD452CC6B3

P2888

Q28072539-3143952C-3B6D-439F-AC23-84F20F3D30CA

P304

Q28072539-757D6FB8-4D5E-4DDB-93EE-284E73C2D9B8

P31

Q28072539-857C230A-93D5-4C24-BEE8-4745B525FD2E

Q28072539-BE1BC076-C49E-4A60-99D7-7BC558762BB8

P3181

Q28072539-16946E33-7D9C-488F-9688-D0B4EA2291BF

P356

Q28072539-3040FC55-E773-4E8F-9364-46DCA05DD4AF

P407

Q28072539-71F9C847-5B6E-4785-A450-CE356620EEE0

P433

Q28072539-99B32935-CB80-4B61-AD98-B47CF1661940

P478

Q28072539-850E4493-FD72-41DB-AFD3-9CA022217F40

P50

Q28072539-5A81047A-B253-41F0-9E33-C4648995E049

P5008

Q28072539-FA1E16C7-0401-4B70-A465-C8A0B8ABDAAC

P577

Q28072539-0B54AA11-4CB8-41E6-A570-13BBF2981D18

P6179

Q28072539-D9C5497F-C291-4B54-9822-48A5BD7E690E

P698

Q28072539-3069F229-8CE2-4477-8B19-981E742BD9CF

P921

Q28072539-48B10071-919D-45ED-A554-30046E302F55

Q28072539-D2F4D2F3-57E7-4AE7-8C7D-F7E7A29C7A99

P932

Q28072539-89F1CC79-A8D2-45FD-B0BF-7435706016CB

P3181

P356

P1433

Blood Cancer Journal

P1476

'Acute myeloid leukemia: a comprehensive review and 2016 update'

@en

P2093

I De Kouchkovsky

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia

The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

P2888

P304

e441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4707028

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/BCJ.2016.50

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050065801

http://www.w3.org/2001/XMLSchema#string

P698

27367478

http://www.w3.org/2001/XMLSchema#string

P921

acute myeloid leukemia

P932

5030376

http://www.w3.org/2001/XMLSchema#string